Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
antibody drug conjugates
Biotech
MacroGenics pulls plug on ADC after seeing phase 2 survival data
MacroGenics has made the call to abandon work on one of its more advanced antibody-drug conjugates after taking a look at the latest phase 2 data.
James Waldron
Mar 21, 2025 7:15am
Zymeworks withholds one ADC from clinic in favor of another
Mar 6, 2025 10:25am
ALX lays off 30% of staff to pay for more trials of CD47 blocker
Mar 5, 2025 9:40am
Frazier arms Callio with $187M series A to fly Hummingbird's ADC
Mar 3, 2025 9:00am
Vincerx left mulling future as Oqory reverse merger falls apart
Mar 2, 2025 1:49pm
OS Therapies sets up subsidiary to seek ADC joint ventures
Feb 24, 2025 9:30am
